Targeting Pattern Recognition Receptors (PRR) offers the potential to normalize chronic persistent inflammatory responses observed in some malignancies or improve defective innate immune sensing inside the tumor micro-environment. This strategy could be used to activate both innate and adaptive anti-tumor immune responses and treat patients who do not respond well to T- cell checkpoint therapies